The FCCC-PENN Ovarian SPORE Program has long believed that support of innovative developmental Pilot Projects have been essential to increase translational research at the Center and to provide important seed funding for new projects. For example, George Coukos'current Project 4 arose out of pilot funds for his project in year 4 of the SPORE. Paul Cairns Project 1 in this current SPORE is an extension of pilot funding in year 6 and 7 of the SPORE and Lin Zhang's Project 3 is an extension of pilot funds delivered in years 8 and 9 of the SPORE. FCCC-PENN has consequently committed substantial institutional resources to support innovative Pilot Projects which have also been supported by the American Cancer Society (ACS) Institutional Grant, developmental funds from the P30 CCSG Core Grant, and from Tobacco Settlement Funds obtained from the State of Pennsylvania. As we look forward to our 11'^ through 15'^ year of funding we are excited about the significant augmentation of developmental pilot program support through increased institutional support to supplement SPORE funds. Consequently, the Ovarian SPORE Developmental Research Program, as outlined in the initial Ovarian SPORE application, was established in an environment at FCCC-PENN which places a high priority on developmental research and recognizes that a successful program requires institutional support together with peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA083638-11
Application #
7727504
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2009-08-21
Project End
2014-05-31
Budget Start
2009-07-01
Budget End
2010-05-31
Support Year
11
Fiscal Year
2009
Total Cost
$61,309
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 25:1384
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Chiang, Cheryl Lai-Lai; Kandalaft, Lana E (2018) In vivo cancer vaccination: Which dendritic cells to target and how? Cancer Treat Rev 71:88-101
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7
Beck, Tim N; Smith, Chad H; Flieder, Douglas B et al. (2017) Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1. Head Neck 39:E34-E39
Yang, Lu; Zhang, Youyou; Shan, Weiwei et al. (2017) Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 9:
Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637
Zhang, Dongmei; Zhang, Gao; Hu, Xiaowen et al. (2017) Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Res 77:3745-3757
Prudnikova, Tatiana Y; Chernoff, Jonathan (2017) The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases 8:193-198

Showing the most recent 10 out of 323 publications